There were several outcomes from the inaugural session of the Cannabis Control Board (CCB) in New York, held on October 5, 2021. The meeting revealed that the CCB and the Office of Cannabis Management (OCM) will be increasing their staff and taking steps to expand the medical coverage of the cannabis program and cannabinoid hemp licensing. Also at the meeting, Jason Starr was announced and elected as OCM’s Chief Equity Officer. He will work with Executive Director Chris Alexander in building New York’s Social Justice Program.
Extension of the medical marijuana program
As discussed during the meeting, the New York Department of Health (DOH) will transfer leadership of the New York Medical Cannabis Program to the OCM. In practice, the OCM takes the following steps, all of which are immediate: (i) Under state law, anyone legally empowered to prescribe a restricted drug can now prescribe marijuana; (iii) the maximum patient marijuana supply increased to 60 days; (iii) registered organizations allow whole flower (an approved form of medicinal cannabis product) to be sold to eligible patients; and (iv) Patients and Healthcare Professionals are no longer required to pay a US $ 50 registration fee.
The other major expansion problem that Chairwoman Tremaine Wright highlighted was the expansion of qualified clinical physicians who can verify medical patients to include any professional licensed to administer a restricted drug. The CCB will work hard to ensure that the health community is aware of this development and is ready to begin certifying patients. They also hope that the introduction of whole flowers will encourage patient involvement in the program due to the drop in product price that comes with that adjustment.
Introduction of the cannabinoid hemp program
The CCB also announced that the New York cannabis hemp licensing process will be moved from the Department of Health to the OCM as part of its cannabinoid hemp program. Chair Tremaine Wright presented some data on the number of license applications currently being filed and stated that cannabis hemp guidelines and guidelines are a priority. The CCB gave a brief summary of the number of hemp licenses received: over 2,700 today; 384 of these were for distributor licenses, 36 processors, 34 for manufacturer licenses and the remaining 2,275 for store licenses. The CCB plans to continue working in the coming months to ensure the continued growth of the cannabinoid hemp program.
No announced timeframe for issuing rules and regulations for adult use
The CCB also discussed the expected timeframe for the publication of laws and regulations on adult cannabis use. Although the CCB has approved and authorized 22 new employees, there is still no public announcement as to when the CCB and OCM can expect the rules to be published.
Once staffing has begun, the office will launch a full public awareness campaign. This campaign will educate the public on key elements of the legislation and improvements to the medical program, including safety advice on avoiding drug-driving, educating patients on the correct storage of their cannabis products, and issues of particular concern to adolescents, pregnant women and nursing homes . Purpose of use.